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Cyclic 3,5-adenosine monophosphate (cAMP) and cyclic 3,5-guanosine monophos-
phate (cGMP) are important second messengers that play a central role in mediating a
variety of functional responses to hormones and other cellular transmitters (1–4). Sensi-
tivity of the physiological processes regulated by cyclic nucleotides requires precise and
rapid regulation of the level of these second messengers according to the requirements
of the physiological status of the cell. Precise modulation of the phosphodiesterase
(PDE) function is critical for maintaining cyclic nucleotide levels within a narrow con-
centration range. Due to their key role in the regulation of physiological processes, inhibi-
tors of PDEs can be used as therapeutic tools for various diseases. Relatively less em-
phasis, however, has been placed on the development of agents that interfere with the
103
Acta Pharm. 61 (2011) 103–113 Short communication
DOI: 10.2478/v10007-011-0009-3
Synthesis and cAMP-dependent phosphodiesterase
inhibition of novel thiazoloquinazoline derivatives
THEIVENDREN PANNEER SELVAM1*
PALANIRAJAN VIJAYARAJ KUMAR2
1 Department of Biotechnology
Acharya Nagarjuna University
Guntur-522510, India
2 Department of Pharmacy, College
Sadaya, International University
Jalan Menara Gading 56000 Cheras
Kuala Lumpur, Malaysia
Accepted February 16, 2011
The series of 6,7,8,9-tetrahydro-5H-5-(2’-hydroxyphenyl)-
-2-(4’-substituted benzylidine)thiazolo(2,3-b)quinazolin-
-3(2H)-ones (4a-j) and 6,7,8,9-tetrahydro-5H-5-(2’-hydro-
xyphenyl)-2-(4’-substituted benzylidine)-3-(4-nitrophenyl
amino)thiazoloquinazolines (5a-j) were synthesized by the
reported method and evaluated for their phosphodieste-
rase inhibitory activity. All test compounds exhibited good
activity. The structure-activity relationships were also stu-
died. In both series of compounds, electron-withdrawing





zoline (5j) and 6,7,8,9-tetrahydro-5H-5-(2’-hydroxyphenyl)-2-
-(4’-chlorobenzylidine)-3-(4-nitrophenylamino)thiazoloqui-
nazoline (5f) were found to be more potent than theop-
hylline (IC50 in mmol L–1 of 1.34 ± 0.09 for 5f, 1.44 ± 0.02
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catabolism of cAMP and cGMP via inhibition of phosphodiesterase. A variety of nitro-
gen and sulfur containing heterocycles are reported to inhibit PDE (5–10). Quinazolines
and condensed quinazoline such as hoquizil, prazosin and buqineran, possess PDE in-
hibitory (11, 12) antimicrobial (13), antiinflammatory (14), anticonvulsant (15) and anti-
hypertensive (16) activity (Fig. 1). Based on these observations, a hypothetical model has
been proposed, taking into account the following broad objectives: to develop new fused
heterocycles expected to exert PDE inhibitory activity similar to that of theophylline.
Based on this approach, we attempted to synthesize 6,7,8,9-tetrahydro-5H-5-(2’-hy-
droxyphenyl)-2-(4’-substituted benzylidine)thiazolo(2,3-b)quinazolin-3(2H)-one (4a-j) and
6,7,8,9-tetrahydro-5H-5-(2’-hydroxyphenyl)-2-(4’-substituted benzylidine)-3-(4-nitrophe-
nylamino)thiazoloquinazolines (5a-j) analogues. The PDE inhibitory activity for all title
compounds (4a-j and 5a-j) was tested using a standard technique (4).
EXPERIMENTAL
Bovine heart phosphodiesterase sample was obtained from Sigma (India) and theo-
phylline, as a reference compound, from German Remedies (India).
Melting points were taken in an open capillary tube and were uncorrected. IR spec-
tra were recorded in KBr pellets (ABB Bomem FT-IR spectrometer MB 104, ABB Limited,
India). The 1H-NMR spectra were recorded in CDCl3 (Bruker 400 NMR spectrometer,
IET Limited) with TMS as internal reference. Mass spectral data were recorded with a
quadrupol mass spectrometer (Shimadzu GC MS QP 5000, Japan). Microanalyses were
performed using a Vario EL V300 elemental analyzer (Elemental Analysensysteme GmbH,
Germany). The purity of the compounds was checked by TLC on pre-coated SiO2 gel
(HF254) aluminium plates (Merck, USA) using ethyl acetate/benzene (1:3) and visuali-
zed in a UV chamber. Physico-chemical and spectral data results of these compounds are
shown in Table I.
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Fig. 1. Quinazoline bearing drugs.
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The target novel thiazoloquinazoline derivatives were synthesized by the previous-
ly reported method (17). The key intermediate and target compounds are illustrated in
Scheme 1.
2-Hydroxybenzylidine cyclohexanone (1). – Equimolar quantities of each cyclohexano-
ne (0.039 mol) and salicylaldehyde (0.039 mol) were taken in a beaker; to this, sodium
hydroxide solution was added to make the solution alkaline. This was shaken and kept
aside. The solid thus obtained was filtered, washed with water and recrystallized from
absolute ethanol.
4-Hydroxy phenyl 3,4,5,6,7,8-hexahydroquinazolin-2-thione (2). – A mixture of 2-hydroxy-
benzylidine cyclohexanone (1) (0.039 mol), thiourea (0.03 mol) and potassium hydroxide
(2.5 g) in 95 % ethanol (100 mL) was heated under reflux for 3 h. The reaction mixture
was concentrated to half its volume, diluted with water, then acidified with glacial acetic
acid and kept overnight. The solid thus obtained was filtered, washed with water and
recrystallized from ethanol to give 2.
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6,7,8,9-Tetrahydro-5H-5-(2’-hydroxyphenyl)thiazolo(2,3-b)quinazolin-3(2H)-one (3). – Chlo-
roacetic acid (0.096 mol) was melted on a water bath and 2 (0.009 mol) was added por-
tionwise to maintain homogeneity. The homogeneous mixture was heated on a water
bath for 30 min and kept overnight. The solid thus obtained was washed with water and
recrystallized from ethanol to give 3.
6,7,8,9-Tetrahydro-5H-5-(2’-hydroxyphenyl)-2-(4’-substituted benzylidine)thiazolo(2,3-b) qui-
nazolin-3(2H)-ones (4a-j). – A mixture of 3 (0.002 mol), substituted benzaldehyde (0.002
mol) and anhydrous sodium acetate (0.002 mol) in glacial acetic acid (10 mL) was heated
under reflux for 4 h. The reaction mixture was kept overnight and the solid thus sepa-




amino)thiazoloquinazolines (5a-j). – A reaction mixture of the respective quinazolin-3(2H)-one
4a-j (0.004 mol) was dissolved in (0.004 mol) thionyl chloride. To this, DMF (0.004 mol)
was added to get chloro derivates. The reaction mixture was then coupled with p-nitro-
anilines (0.004 mol) in DMF at 80 °C for 3 h. After the mixture was cooled, the precipitate




Inhibition of bovine heart phosphodiesterase was determined by the known method
(2).
PDE activity was calculated by measuring the production of inorganic phosphates
in the presence of an excess of 5-nucleotidase. Each sample contained 1 mmol L–1 cAMP,
3 mmol L–1 MgSO4, 5-nucleotidase (0.02 units mL–1) and bovine heart phosphodieste-
rase (0.002 units mL–1), and appropriate concentration of the test compound in ethanol
and Tris-HCl buffer (pH 7.5, 50 mmol L–1), in a final volume of 1 mL. The reagents com-
prising 0.4 mL acid molybdate solution, 0.4 mL Elon reducing agent, and 1.0 mL H2O, to
give a final volume of 3.0 mL, were mixed in an incubation vessel, and the reaction was
initiated by addition of cAMP and allowed to proceed for 20 min over a 30 °C water
bath. The reaction was terminated by addition of 0.2 mL 5 % trichloroacetic acid. The so-
lution was then vortexed and centrifuged at 800´g for 10 min. Color was allowed to de-
velop for 20 min and absorbance was measured at 660 nm. The results given in Table II
are expressed as the concentration of inhibitor giving 50 % inhibition (IC50) of the cAMP-
-dependent PDE activity. The IC50 value was determined from plot of percentage inhibi-
tion vs. varying concentration of the inhibitor compounds 4a-j and 5a-j. To validate the
enzyme assay method, the IC50 value of theophylline as a standard inhibitor was also
determined.
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RESULTS AND DISCUSSION
Chemistry
The series of heterocycles 4a-j and 5a-j were synthesized by the reaction of 3 with
appropriate aromatic aldehyde and p-nitroaniline in the presence of anhydrous sodium
acetate and DMF as it is presented in Scheme 1. The IR, 1H NMR, mass spectroscopy and
elemental analyses for the new compounds were in accord with the assigned structures.
The IR spectra of compounds 4a-j showed stretching bands of the keto group at
1715–1740 cm–1. In 5a-j, stretching and bending NH bands of thiazoloquinazoline moiety
appear at 3300–3400 and 1300–1350 cm–1, respectively. The recorded IR spectra of com-
pounds 5a-j showed no keto group bands. This clearly envisages that the keto group of
4a-j is converted into secondary NH. In 5a-j, the NH signal of 3-(4-nitrophenyl)amino-
thiazoloquinazoline moiety appear at d 7.26 (s), 7.23 (s), 7.29 (s), 7.69 (s), 7.34 (s), 7.16 (s),
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Table II. PDE inhibition and relative data of synthesized compounds
Compd. IC50 (mmol L–1) Relative activity
4a 2.10 ± 0.09 1.22
4b 2.40 ± 0.02 1.35
4c 2.33 ± 0.09 1.34
4d 2.28 ± 0.02 1.27
4e 2.09 ± 0.08 1.22
4f 2.11 ± 0.08 1.21
4g 2.13 ± 0.08 1.28
4h 2.32 ± 0.08 1.32
4i 2.41 ± 0.03 1.35
4j 2.64 ± 0.02 1.47
5a 1.98 ± 0.03 1.09
5b 2.12 ± 0.04 1.20
5c 2.09 ± 0.05 1.18
5d 2.03 ± 0.04 1.14
5e 1.44 ± 0.02 0.87
5f 1.34 ± 0.09 0.84
5g 1.64 ± 0.04 0.93
5h 2.07 ± 0.06 1.18
5i 2.07 ± 0.03 1.17
5j 1.52 ± 0.05 0.87
Theophylline 1.72 ± 0.09 1
Solvent used: DMSO
IC50 values were determined as described in the experimental section. Mean ± SD, n = 3.
7.79 (s), 7.67 (s), 7.42 (s) and 7.19 (s) ppm, respectively. The presence and position of NH
signal in the 1H NMR spectra of final compounds conform with the secondary NH pro-
ton in thiazoloquinazoline moiety. This clearly envisages that thiazole-3-one moiety was
involved in 3-(4-nitrophenyl)amino formation. Mass spectra showed accurate molecular
ion peaks at m/z 300, 478 and 528 for 3, 4h and 5e, resp. All these facts clearly demon-
strated that the 3rd position of keto group in thiazole ring was converted into secondary
amino group, as indicated in Sheme 1 and conforming with the proposed structures 5a-j.
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R1 R2 R3
a – – –
b – –OH –
c – –OCH3 –
d – –CH3 –
e – –F –
f – –Cl –
g – –Br –
h –OCH3 –OCH3 –OCH3
i – –CH3 –CH3




























































The target compounds were evaluated for their ability to inhibit bovine heart phos-
phodiesterase with theophylline chosen as a standard for comparison (Table II). All the
compounds were found to exhibit PDE inhibitory activity. Despite the fact that this as-
say is less sensitive compared to radioisotope PDE assays and likely to underestimate
the relative inhibitory potencies of the test compounds, the results of this evaluation in-
dicate that the quinazoline derivatives are still more potent inhibitors of PDE than theo-
phylline.
Compounds having thiazolo(2,3-b)quinazolin-3(2H)-one (4a-j) and thiazoloquina-
zoline (5a-j) ring systems were all found to exhibit promising PDE inhibitory activity
with IC50 in the range 1.34–2.64 (±0.09) mmol L–1 and activity relative to theophylline of
0.84–1.47. Among them 6,7,8,9-tetrahydro-5H-5-(2’-hydroxyphenyl)-2-(4’-chlorobenzyli-
ne)-3-(4-nitrophenylamino)thiazoloquinazoline (5f) was found to be most potent, with
relative activity of 0.8 compared to the standard, whereas for both compounds 6,7,8,9-te-
trahydro-5H-5-(2’-hydroxyphenyl)-2-(4’-fluorobenzylidine)-3-(4-nitrophenylamino)thiazo-
loquinazoline (5e) and 6,7,8,9-tetrahydro-5H-5-(2’-hydroxyphenyl)-2-(4’-nitrobenzylidine)-
-3-(4-nitrophenylamino)thiazoloquinazoline (5j) relative reactivity was found to be 0.87.
The electronic nature of the substituent groups at second positions in thiazole nu-
cleus led to significant variation in PDE inhibitory activity. In both series the presence of
an electron-withdrawing group (chloro, fluoro, nitro, bromo) in the thiazoloquinazoline
nucleus resulted in higher activity. For example, 4-nitrophenyl amino substitution in thia-
zoloquinazoline nucleus (5a-j) increased activity; the order of activity was Cl > F > NO2 >
Br > electron donating group. Compound 5f, 5e, 5j and 5g showed higher activity than
the reference drug theophylline.
CONCLUSION
In summary, the present study has demonstrated that fused thiazoloquinazolines are
novel inhibitors of phosphodiesterase and may potentially act as smooth muscle relaxa-
tory agents. Further work is in progress to estabilish this observation in different animal
models and find selective inhibitors of PDE 4, which may impact strategies for bron-
chodilator activity.
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S A @ E T A K
Sinteza i cAMP-ovisna inhibicija fosfodiesteraze novih derivata tiazolokinazolina
THEIVENDREN PANNEER SELVAM i PALANIRAJAN VIJAYARAJ KUMAR
U radu je opisana sinteza serije 6,7,8,9-tetrahidro-5H-5-(2’-hidroksifenil)-2-(4’-sup-
stituiranih benzilidin)tiazolo(2,3-b)kinazolin-3(2H)-ona (4a-j) i 6,7,8,9-tetrahidro-5H-5-
-(2’-hidroksifenil)-2-(4’-supstituiranih benzilidin)-3-(4-nitrofenilamino)tiazolokinazolina
(5a-j) prema objavljenoj metodi te ispitano njihovo inhibitorno djelovanje na fosfodies-
terazu. Svi testirani spojevi pokazuju dobro djelovanje. Prou~avan je i odnos strukture i
djelovanja. U obje serije spojeva, elektron-odvla~e}i supstituenti doprinose ja~em djelo-




zolokinazolin (5f) imaju ja~e djelovanje od teofilina (IC50 u mmol L–1 1,34 ± 0,09 za 5f,
1,44 ± 0,02 za 5e, 1,52 ± 0,05 za 5j nasuprot 1,72 ± 0,09 za teofilin).
Klju~ne rije~i: tiazolokinazolin, benzilidinetiazolokinazolin, nitrofenilaminotiazolokinazolin, inhibi-
cija fosfodiesteraze, SAR
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